



Docket No. 4884000

TECH CENTER 1600/2900

FEB 03 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bryan M. O'HARA

Group Art Unit: 1614

Serial No.: 10/010,129

Examiner: TBA

Filed: December 6, 2001

For: NOVEL COMPOUNDS THAT ENHANCE DIMERIZATION OF THE SUBUNITS OF HIV-1 REVERSE TRANSCRIPTASE HAVING MUTATIONS ASSOCIATED WITH RESISTANCE TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: **EV 245 482 952 US**

Date of Deposit: **January 30, 2003**

I hereby certify that the following attached paper(s) and/or fee

1. Information Disclosure Statement (IDS) (1 page);
2. Form PTO-1449 (1 page);
3. Copies of IDS References (9 references);
4. Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231; **BOX: IDS.**

Jafet N. Cotto

(Typed or printed name of person mailing papers(s) and/or fee)


(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



01-31-03

#2

1614

Docket No. 4488-4000

TECH CENTER 1600/2900

FEB 03 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bryan M. O'HARA

Group Art Unit: 1614

Serial No.: 10/010,129

Examiner: TBA

Filed: December 6, 2001

For: NOVEL COMPOUNDS THAT ENHANCE DIMERIZATION OF THE SUBUNITS OF HIV-1 REVERSE TRANSCRIPTASE HAVING MUTATIONS ASSOCIATED WITH RESISTANCE TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
Washington, DC 20231

Sir:

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) _____, filed _____, respectively.

- ☐ This document is being filed within three (3) months of the filing date of the application
- ☐ A check for the requisite fee of \$180 is enclosed.
- ☐ This document is being concurrently filed with the above-identified application.
- ☐ This document is being concurrently filed with an Request for Continued Examination (RCE).
- ☒ This document is being filed prior to a first Office Action on the merits.
- ☐ This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4488-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.Dated: January 30, 2003By: Caryn DeHoratius
Caryn DeHoratius
Registration No. 45,881Correspondence Address:MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:
4488-4000Serial No.:
10/010,129Applicant:
B. M. O'HARAFiling Date:
December 6, 2001Group Art Unit:
1614Page 1 of 2
FEB 03 2003
TECH CENTER 1600/2800
RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Name	Class	Sub-Class	Filing Date
	5,922,856	07/13/1999	Fritz et al.	536	23.72	06/27/1996

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translation
						<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)

	Luban, J., Alin, KB, Bossolt, LK, Humaran T., Goff SP, 1992, "Genetic Assay for Multimerization of Retroviral Gag Polyproteins", J. Virol., 66(8):5157-60.
	Morris, MC, Berducou C., Mery J., Heitz F., Divita G., 1999, "The thumb domain of the P51-subunit is essential for activation of HIV reverse transcriptase," Biochemistry, 38(46):15097-103.
	Legrain P., Dokhelar MC, Transy C., 1994, "Detection of protein-protein interactions using different vectors in the two-hybrid system," 22(15):3241-2.
	Fields, S., Song O., 1989, "A novel genetic system to detect protein-protein interactions," Nature, 340(6230):245-6.
	Hughes, SH, 2001, "Molecular matchmaking: NNRTIs can enhance the dimerization of HIV type 1 reverse transcriptase," Proc Natl Acad Sci USA, 98(13):6991-2.
	Tachedjian, G., Aronson, HE, Goff, SP, 2000, "Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase," Proc Natl Acad Sci USA, 97(12):6334-9.
	Bachelor, L. et al., 2001, "Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy," J. Virol, 75(11):4999-5008.

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:
4488-4000Serial No.:
10/010,129Applicant:
B. M. O'HARAFiling Date:
December 6, 2001Group Art Unit:
1614RECEIVED
FEB 03 2003
TECH CENTER 1800/12900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)

Tachedjian G., Orlova, M., Sarafianos, SG, Arnold E., Goff SP, 2001, "Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase," Proc Natl Acad Sci USA, 98(13): 7188-93. \

752935 v1

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

EV 245 482 952 US